BofA raised the firm’s price target on Nasdaq (NDAQ) to $111 from $105 and keeps a Buy rating on the shares. Following the recent Q3 beat, the firm raised its Q4, 2026 and 2027 EPS estimates due to positive market beta in indexing, upward revenue revisions to the IPO-related businesses and refined estimates for the Solovis divestiture.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NDAQ: